A widely prescribed class of blood pressure medications, dihydropyridine calcium-channel blockers (DCCBs), may be associated with an increased risk of kidney damage in individuals with type 2 diabetes, even when they are already on kidney-protective treatments. This finding, presented at the European Renal Association’s annual congress, raises important questions about current treatment strategies for diabetic kidney disease (DKD).
Key Takeaways
- Dihydropyridine calcium-channel blockers (DCCBs), commonly used for blood pressure control, may increase kidney damage risk in type 2 diabetes patients.
- Patients on DCCBs alongside standard kidney-protective therapies (RAS inhibitors and SGLT2 inhibitors) showed a 33% higher risk of major adverse kidney events.
- The mechanism may involve DCCBs altering blood flow dynamics within the kidneys, potentially increasing pressure.
- Researchers emphasize the need for further studies to confirm these findings and guide treatment decisions.
Understanding the Risk
Diabetic kidney disease (DKD) is a significant complication of type 2 diabetes, often leading to kidney failure. Managing blood pressure is crucial in slowing its progression. For years, renin-angiotensin system (RAS) inhibitors and sodium-glucose cotransporter-2 (SGLT2) inhibitors have been cornerstones of DKD treatment, offering substantial kidney protection.
However, the new research, which analyzed data from over 31,000 adults with type 2 diabetes between 2016 and 2021, suggests that adding DCCBs to these standard therapies migh